Efficacy of 7-day and 14-day potassium-competitive acid blocker-based bismuth-containing quadruple regimen for Helicobacter pylori infection

doi:10.3748/wjg.119668

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 37

This Article

(3)

(0)

(32)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Oct 7, 2026; 32(37): 119668
Published online Oct 7, 2026. doi: 10.3748/wjg.119668

Table 3 Helicobacter pylori eradication rate according to the antibiotic resistance (per-protocol set)

Antibiotic resistance	7-day PC-BMT	14-day PC-BMT	14-day P-BMT	7-day PC-BMT vs 14-day P-BMT		14-day PC-BMT vs 14-day P-BMT
Antibiotic resistance	7-day PC-BMT	14-day PC-BMT	14-day P-BMT	Difference (95%CI)	P value	Difference (95%CI)	P value
Single-resistant strain	81.3% (13/16)	89.7% (26/29)	87.0% (20/23)	-5.7% (-29.3 to 17.9)	0.674	2.7% (-15.0 to 20.4)	> 0.999
Clarithromycin-resistant strain	87.5% (7/8)	90.9% (10/11)	87.5% (7/8)	0.0% (-32.4 to 32.4)	> 0.999	3.4% (-25.1 to 32.0)	> 0.999
Amoxicillin-resistant strain	0.0% (0/1)	50.0% (1/2)	100.0% (2/2)	-100.0% (-100.0 to -100.0)	0.333	-50.0% (-100.0 to 19.3)	> 0.999
Metronidazole-resistant strain	85.7% (6/7)	93.3% (14/15)	84.6% (11/13)	1.1% (-31.4 to 33.6)	> 0.999	8.7% (-14.6 to 32.0)	0.583
Tetracycline-resistant strain	N/A	100.0% (1/1)	N/A	N/A	N/A	N/A	N/A
Dual-resistant strain	75.0% (6/8)	60.0% (3/5)	100.0% (5/5)	-25.0% (-55.0 to 5.0)	0.487	-40.0% (-82.9 to 2.9)	0.444
Clarithromycin and amoxicillin	75.0% (6/8)	33.3% (1/3)	100.0% (4/4)	-25.0% (-55.0 to 5.0)	0.515	-66.7% (-100.0 to -13.3)	0.143
Clarithromycin and metronidazole	N/A	100.0% (2/2)	100.0% (1/1)	N/A	N/A	N/A	> 0.999
Multiple-resistant strain	N/A	100.0% (1/1)	N/A	N/A	N/A	N/A	N/A
No antibiotic-resistant strain	80.0% (28/35)	91.3% (21/23)	82.1 % (23/28)	-2.1% (-21.6 to 17.3)	0.830	9.2% (-9.1 to 27.4)	0.436
Culture no growth	84.0% (42/50)	87.0% (40/46)	72.0% (36/50)	12.0% (-4.1 to 28.1)	0.148	15.0% (-0.9 to 30.8)	0.083

N/A: Not applicable; P-BMT: Proton pump inhibitor-based bismuth-containing quadruple regimen; PC-BMT: Potassium-competitive acid blocker-based bismuth-containing quadruple regimen.

Full Size Table

Citation: Oh CK, Lim H, Noh JH, Gong EJ, Seo SI, Bang CS, Kim YJ, Shin WG, Kim JB, Jang HJ, Baik GH. Efficacy of 7-day and 14-day potassium-competitive acid blocker-based bismuth-containing quadruple regimen for Helicobacter pylori infection. World J Gastroenterol 2026; 32(37): 119668
URL: https://www.wjgnet.com/1007-9327/full/v32/i37/119668.htm
DOI: https://dx.doi.org/10.3748/wjg.119668

Oh CK, Lim H, Noh JH, Gong EJ, Seo SI, Bang CS, Kim YJ, Shin WG, Kim JB, Jang HJ, Baik GH. Efficacy of 7-day and 14-day potassium-competitive acid blocker-based bismuth-containing quadruple regimen for Helicobacter pylori infection. World J Gastroenterol 2026; 32(37): 119668 [DOI: 10.3748/wjg.119668]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.